Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models.

Rothschilds A, Tzeng A, Mehta NK, Moynihan KD, Irvine DJ, Wittrup KD.

Oncoimmunology. 2019 Feb 19;8(5):e1558678. doi: 10.1080/2162402X.2018.1558678. eCollection 2019.

PMID:
31069130
2.

Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles.

Yang YS, Moynihan KD, Bekdemir A, Dichwalkar TM, Noh MM, Watson N, Melo M, Ingram J, Suh H, Ploegh H, Stellacci FR, Irvine DJ.

Biomater Sci. 2018 Dec 18;7(1):113-124. doi: 10.1039/c8bm01208c.

PMID:
30444251
3.

Cell and fluid sampling microneedle patches for monitoring skin-resident immunity.

Mandal A, Boopathy AV, Lam LKW, Moynihan KD, Welch ME, Bennett NR, Turvey ME, Thai N, Van JH, Love JC, Hammond PT, Irvine DJ.

Sci Transl Med. 2018 Nov 14;10(467). pii: eaar2227. doi: 10.1126/scitranslmed.aar2227.

PMID:
30429353
4.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.

Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E, Tregoning JS, Irvine DJ, Barouch DH.

J Immunol. 2018 Nov 1;201(9):2744-2752. doi: 10.4049/jimmunol.1800885. Epub 2018 Sep 24.

5.

Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.

Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, Liang S, Abraham W, Melo MB, Zhang AQ, Li N, Gall SL, Pentelute BL, Irvine DJ.

Cancer Immunol Res. 2018 Sep;6(9):1025-1038. doi: 10.1158/2326-6066.CIR-17-0607. Epub 2018 Jun 18.

6.

Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide.

Appelbe OK, Moynihan KD, Flor A, Rymut N, Irvine DJ, Kron SJ.

J Control Release. 2017 Nov 28;266:248-255. doi: 10.1016/j.jconrel.2017.09.043. Epub 2017 Oct 5.

7.

Roles for Innate Immunity in Combination Immunotherapies.

Moynihan KD, Irvine DJ.

Cancer Res. 2017 Oct 1;77(19):5215-5221. doi: 10.1158/0008-5472.CAN-17-1340. Epub 2017 Sep 19. Review.

8.

High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry.

Yang YS, Atukorale PU, Moynihan KD, Bekdemir A, Rakhra K, Tang L, Stellacci F, Irvine DJ.

Nat Commun. 2017 Jan 17;8:14069. doi: 10.1038/ncomms14069. Erratum in: Nat Commun. 2017 Aug 14;8:15343.

9.

Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy.

Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, Moynihan KD, Kolls JK, Irvine DJ, Artyomov MN, Rangel-Moreno J, Khader SA.

Nat Commun. 2016 Dec 22;7:13894. doi: 10.1038/ncomms13894.

10.

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD.

Cell Rep. 2016 Dec 6;17(10):2503-2511. doi: 10.1016/j.celrep.2016.11.020.

11.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

12.

Engineering New Approaches to Cancer Vaccines.

Mehta NK, Moynihan KD, Irvine DJ.

Cancer Immunol Res. 2015 Aug;3(8):836-43. doi: 10.1158/2326-6066.CIR-15-0112. Epub 2015 Jul 8. Review.

13.

Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, Melo MB, Mueller S, Irvine DJ.

J Clin Invest. 2015 Jun;125(6):2532-46. doi: 10.1172/JCI79915. Epub 2015 May 4.

14.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD.

Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.

15.

Structure-based programming of lymph-node targeting in molecular vaccines.

Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Egeren DS, Park C, Irvine DJ.

Nature. 2014 Mar 27;507(7493):519-22. doi: 10.1038/nature12978. Epub 2014 Feb 16.

Supplemental Content

Loading ...
Support Center